Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength
Source: SeekingAlpha
2026-02-19 11:28:56 ET
Bristol-Myers Squibb Company ( BMY ) shares have risen 27.7% since my last article , " Why Bristol-Myers Squibb Remains Undervalued In 2025," in mid-November. They have outperformed the S&P 500 [3.6% return] ( SPY ) during that time....
Read the full article on Seeking Alpha
For further details see:
Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength
Cytokinetics Incorporated
NASDAQ: CYTK
CYTK Trading
3.12% G/L:
$61.71 Last:
1,189,320 Volume:
$60.35 Open:
CYTK Latest News
March 09, 2026 02:38:32 pm
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
February 24, 2026 04:00:00 pm
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
CYTK Stock Data
$7,892,201,167
118,963,776
0.07%
158
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
